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was based on the average monthly salary in the UK. A conservative assumption was 
made about the increased risk of a productive day being lost – associated with level 
of patient satisfaction to their treatment – by calculating an approximate number of 
unscheduled hospitalisations that users of a new inhaler would experience in the 
previous 12 months relative to Spiriva® HandiHaler®. Patient satisfaction with their 
inhaler was based on inhaler features that relate to ease of use and ergonomics and 
compared Spiriva® HandiHaler® to an improved inhaler. Results: The frequency 
of unscheduled hospitalisations for the new inhaler and Spiriva® HandiHaler® users 
were calculated at 0.34 and 0.38, resulting in 68 and 76 productive days lost annually, 
respectively. The total annual societal cost per patient was € 9,851 with the new inhaler 
and € 10,891 with Spiriva® HandiHaler®. The new inhaler costs € 1,040 less per annum 
than Spiriva® Handihaler®. ConClusions: New inhalers with improved features 
have the potential to offer substantial societal cost savings in COPD compared with 
Spiriva® Handihaler®.
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objeCtives: A real-life cost-effectiveness evaluation in 2008 showed that medica-
tion costs of budesonide/formoterol for maintenance and reliever therapy (MART) 
via dry powder inhaler (DPI) was significantly lower than medication costs associ-
ated with fixed-dose combination (FDC) of budesonide/formoterol in conventional 
way (FDC of ICS/LABA + additional reliever) and free adjustable combination (FAC) 
of budesonide and formoterol, with at least equal effectiveness. In 2014 the Dental 
and Pharmaceutical Benefits Agency (TLV) in Sweden assessed all inhaled corticos-
teroids (ICS), long-acting beta-2-agonists (LABA) and their FDCs where the outcomes 
suggested equal effectiveness across treatment strategies and a pricing corridor was 
implemented. The objective is to update the medication costs for a real-life cost-
effectiveness analysis of treating asthma in Swedish primary care and to evaluate 
the medication costs in Denmark. Methods: Medication costs from 2006 included 
all pharmaceuticals in the analysis which were inflated to 2015 price levels and then 
compared to today’s actual prices of medications used in the FAC arm (Pulmicort® 
Turbuhaler® & Oxis® Turbuhaler®, plus terbutaline as needed), FDC arm (Bufomix® 
Easyhaler® plus terbutaline as needed) and the budesonide/formoterol MART arm 
(DuoResp® Spiromax®). The same analysis was conducted for both Sweden and 
Denmark. Results: The medication costs in the budesonide/formoterol MART arm 
is less costly when considering DuoResp® Spiromax®, SEK 3336.4 (SEK 4710.9) per 
patient and year compared to SEK 4163 (SEK 6157) in the FDC arm and SEK 7498.5 
(SEK 5637.6) FAC arm. In Denmark the same trend is visible where the MART arm 
was DK 4183.5 (DK 4573) compared to DK 4579 (DK 5905.2) in the conventional FDC 
arm and 4510.4 (DK 4511.7) in the FAC arm. ConClusions: Compared to conven-
tional treatment arm (FDC + reliever) and free adjustable combination (FAC) arm, 
DuoResp® Spiromax® with MART usage has the potential to be cost saving option 
with at least equivalent efficacy.
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objeCtives: This study aimed at estimating the cost-effectiveness of the fixed-dose 
combination indacaterol/glycopyrronium 85/43μ g (IND/GLY) against tiotropium 18μ g 
(TIO) and salmeterol/ fluticasone 50/500μ g (SFC) in the management of patients with 
COPD in Greece. Methods: A microsimulation model was developed in MS Excel. 
Efficacy and utility data were obtained from the international literature (SHINE & 
ILLUMINATE studies) and mortality data from the WHO database. Distribution of 
patients by GOLD severity stage, maintenance costs and costs associated with severe/ 
non-severe exacerbations were taken from published Greek studies. Unit costs were 
taken from officially published sources (Price Bulletin, reimbursement list, DRGs). The 
study perspective was that of the Social Insurance Fund; costs and outcomes were 
discounted at 3.5%; outcomes are reported over time horizons of one, three, five and 
10 years and over a lifetime. Cost base year was 2014. Deterministic and probabilistic 
sensitivity analyses were conducted to test robustness of model results. Results: 
Treatment of COPD with IND/GLY is associated with increased efficacy both against 
SFC (additional life years [LYs]: 0.19; additional quality adjusted life-years [QALYs]: 
0.13) and TIO (additional LYs: 0.22; QALYs: 0.16). Although IND/GLY has a higher 
pharmaceutical cost (additional € 2,626 vs. SFC; additional € 2,679 vs. TIO), all other 
cost components (maintenance costs, severe and non-severe exacerbation costs) 
are reduced, resulting in a reduction of total costs by € 5,204 compared with SCF 
and € 7,126 compared with TIO. The sensitivity analyses confirmed that IND/GLY 
was dominant in the majority of iterations, with a probability of being cost effective 
at a threshold of € 30,000 per QALY gained of 99.9% and 97.1% versus SFC and TIO, 
respectively. ConClusions: IND/GLY was found to be a dominant treatment strategy 
compared to SFC and TIO for the management of patients with COPD in Greece, which 
could lead to savings for the healthcare system.
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(r = 0.09 with Spearman and Pearson tests). ConClusions: There is a decrease in 
the COPD hospitalizations after the introduction of the new inhaled medicines and 
increase in their cost due to increase in the cost of services.
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objeCtives: Long-acting β 2-agonists (LABAs) and long-acting muscarinic antago-
nists (LAMAs) have shown efficacy in preventing exacerbations in patients with 
COPD. Though these agents are effective in the treatment of COPD, deterioration 
in the patient health status can persist and therefore there is a need for improved 
treatment outcomes. In the SPARK trial, dual bronchodilation with QVA149 demon-
strated advantages in reducing the risk of COPD exacerbations in severe and very 
severe patients when compared to single bronchodilation with tiotropium. The 
objective of the study was to stimate the clinical benefits and the budget impact 
associated with the use of indacaterol 110 μ g/glycopyrronium 50 μ g (QVA149) instead 
of tiotropium 18 μ , in severe and very severe COPD patients (GOLD C and D) in 
Portugal. Methods: A cost-consequence model was developed using the SPARK 
study data to derive treatment outcomes associated to the use of QVA149 instead 
of tiotropium. Primary outcomes of interest were COPD exacerbations and direct 
cost for the NHS. Treatment outcomes and costs were estimated for a 1 year. Local 
data was used to identify the target population, resource use and overall treat-
ment costs. Results: It is estimated that there are 11,239 GOLD C and D patients 
treated with tiotropium. Assuming that 20.5% of COPD patients see their primary 
care doctor with complaints about symptoms and exacerbations 2,304 of those 
patients could be treated instead with QVA149. After 1 year of treatment with QVA 
149 it is estimated that patients will experience 1,291 fewer exacerbations with a 
reduction of € 136,544 in the overall treatment costs compared to treatment with 
tiotropium. ConClusions: Symptom control in COPD is essential and evidence 
shows that dual bronchodilation with QVA149 brings benefits when compared to 
tiotropium. The use of QVA149 in symptomatic patients instead tiotropium may 
improve treatment outcomes and reduce overall costs for the Portuguese NHS.
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objeCtives: In the LANTERN study QVA149 significantly reduced the rate of mod-
erate or severe exacerbations by 31% (p= 0.048) over Salmeterol/Fluticasone (SFC). 
The evidence suggests that the use of QVA149 can optimize treatment outcomes 
in patients with mild-to-severe COPD but at what cost to the Portuguese NHS? 
The study objective was to quantify the potential clinical benefits and the budget 
impact associated with the use of QVA149 and SFC in the treatment of Portuguese 
patients with moderate-to-severe COPD with few or no exacerbations. Methods: 
A cost-consequence model was developed using the LANTERN study data to derive 
treatment outcomes for QVA149 and SFC. Primary outcomes of interest were COPD 
exacerbations (total, moderate and severe) and direct cost for the Portuguese NHS. 
Treatment outcomes and costs were estimated for 1 year time horizon. Local data 
was used to identify the target population, resource uses and overall treatment 
costs. Results: It is estimated that there are 73,739 GOLD B patients diagnosed 
and treated in Portugal and 34,778 of those patients are treated with SFC and could 
be eligible to receive treatment with QVA149. After one year of treatment with SFC 
it is estimated that these patients may experience 30,605 exacerbations (15,650 
moderate/severe) with a total treatment cost of € 69,268,710. If treated with QVA149 
it is estimated that these patients may experience 6,608 fewer exacerbations (4,869 
fewer moderate/severe) with a total treatment cost saving of € 8,524,307 versus SFC 
treatment. ConClusions: The analysis suggest that once a day QVA149 can pro-
vide better treatment outcomes in patients with COPD with fewer treatment costs 
for the Portuguese NHS when compared with twice a day SFC in the treatment of 
moderate-to-severe COPD with few or no exacerbations.
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objeCtives: Spiriva® Handihaler® (tiotropium) is available in a single capsule 
dry powder inhaler (DPI) for the treatment of COPD. As exacerbations and hospi-
talisations represent an important driver of the cost and morbidity of COPD, high 
priority should be given to interventions aimed at delaying the progression of dis-
ease, preventing exacerbations, and reducing the risk of comorbidities to alleviate 
the clinical and economic burden of disease. The potential societal cost benefits of 
improving treatment satisfaction, due to improved characteristics of an inhaler were 
investigated. Methods: The eligible adult patient population was based on con-
firmed COPD diagnoses in UK, with the proportion of patients receiving Spiriva® 
Handihaler® based on market research data. The annual number of work days lost 
due to COPD was based on data from the UK. The monetary value of a productive day 
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objeCtives: To investigate whether Budesonide Easyhaler is a cost – effec-
tive treatment option in the Russian Federation, compared to Pulmicort 
Turbuhaler. Methods: Information search was conducted in the public domain. 
Pharmacoeconomic analysis method “cost – effectiveness analysis” and direct 
cost analysis were performed. Results: The information search performed in the 
course of this study yielded outcomes of the Budesonide Easyhaler and Pulmicort 
Turbuhaler therapies in the treatment of asthma that used two effectiveness cri-
teria: improvement in lung function (peak expiratory flow – PEF) and decline the 
number of asthma exacerbations. These results are described in the publication of 
T. Vanto 2004. Then was calculated the direct cost of the various medications per 
patient. Cost analysis was conducted on the cost of basic pharmacotherapy (daily 
dose – 0,4mg), compensation costs for treatment of exacerbations, compensation 
costs for side effects and adverse reactions. The study had a time frame of one year. 
The total cost per one patient with asthma amounted to 4 727,79$ to the Budesonide 
Easyhaler group and 5 507,92$ to the Pulmicort Turbuhaler group. In the last stage, 
effectiveness parameters were obtained. They made 36 283,87$ and 47 116,55$ for 
improvement in lung function criterion, 1 477,43$ and 3 059,96$ for decline the 
number of asthma exacerbations criterion to the Easyhaler and Turbuhaler groups 
respectively. ConClusions: As a result of the cost – effectiveness analysis was 
demonstrated that Budesonide Easyhaler therapy was the dominant treatment 
option, being associated with lower cost per effectiveness unit when improvement 
in lung function and decline the number of asthma exacerbations were utilized as 
the effectiveness criterion.
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objeCtives: To evaluate the long-term cost-effectiveness of RMTAC (an adjunct 
pharmaceutical asthma management) vs. usual physician care clinic by using deci-
sion analytic modelling method. Methods: A dynamic adherence asthma Markov 
cohort model was developed. The economic evaluation was based on a lifetime 
horizon and cycle length of one month, from the healthcare provider‘s (Ministry 
of Health) perspective, with the outcomes assessed in cost per QALY gained and 
cost per hospitalization averted. Probabilities of asthma control-adherence states 
from RMTAC database, costs from national sources, utilities using standard gam-
ble method on Malaysia’s asthma patients, and other inputs from secondary data 
sources were used to inform the probabilistic model, according to gender and age 
subgroups. A scenario analysis was conducted to test the structural assumption on 
follow-up visits after the final treatment visit. Results: In female subgroup, RMTAC 
management dominates the usual care by having 0.91 (95% CI 0.24 – 1.69) QALY 
gained and 0.58 (95% CI -2.30 – 6.23) hospitalization averted, at a lower cost. For male 
subgroup, the ICERs were RM10 (95% CI -RM14431 – RM8323) per QALY gained and 
RM18 (95% CI -RM35790 – RM30266) per hospitalization averted. At the willingness-
to-pay threshold of RM29000 per an additional QALY gained, the RMTAC intervention 
is likely to be cost-effective 99% and 57% of the time (for QALY and hospitalization 
outcome, respectively). The analysis was robust to assumptions of follow-up visits 
frequency and patients’ gender. ConClusions: Implementing RMTAC in Malaysia 
has high probability of being more cost-effective than the usual care management 
for both male and female subgroups across all age groups. Further investigation is 
necessary to ensure that implementing this decision does not exceed the overall 
national healthcare expenditure.
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objeCtives: Asthma is one of the most common chronic diseases globally. Its 
symptoms and inadequate control, which may lead to exacerbations, could impact 
on health related quality of life and health outcomes. The objective is to assess the 
cost-effectiveness of daily 5 mcg tiotropium combined with conventional treat-
ment (CT) (high-dose inhaled corticosteroids and long-acting beta2 agonists) ver-
sus CT alone for the treatment of adult patients with persistent severe asthma in 
Spain. Methods: A Markov model was developed with 7 health states, accord-
ing to severity of exacerbations and asthma control, defined by Asthma Control 
Questionnaire (ACQ-6) results. A lifetime horizon and a Spanish National Health 
System perspective were considered, including direct medical costs (pharmaco-
logical costs and management costs for each health state). A 3% discount rate was 
applied to cost and health outcomes. Efficacy data were obtained from 205.416 and 
205.417 clinical trials, utility values from the literature, and costs from Spanish 
National databases. In order to assess the robustness of the model results, proba-
bilistic and deterministic univariate sensitivity analyses (SA) were performed 
modifying time horizon, discount rate and health state costs. Results: The model 
evaluated costs and efficacy of each alternative for severe asthma treatment, meas-
ured as quality-adjusted life year (QALY) gained. Tiotropium plus CT was asso-
ciated with 15 QALY gained and € 83,122 costs versus 14.79 and € 80,430 with CT 
alone. The incremental cost-utility ratio for tiotropium plus CT was € 12,985/QALY. 
Univariate and probabilistic SA results were robust according to the base case sce-
nario. Tiotropium therapy was a cost-effective alternative in 74.7% of simulations 
performed. ConClusions: Considering the current Spanish cost-effectiveness 
objeCtives: Umeclidinium/vilanterol (UMEC/VI) is a novel fixed dose combination 
of a long acting muscarinic (LAMA) and a long acting beta agonist (LABA) agents. 
The objective of this analysis was to evaluate the incremental cost-effectiveness 
ratio (ICER) of UMEC/VI compared with Tiotropium (TIO), from the Spanish National 
Health System (NHS) perspective. Methods: A previously published linked equa-
tions cohort model based on the epidemiological longitudinal study ECLIPSE was 
used. Patients included were COPD patients with a post-bronchodilator forced expir-
atory volume in one second (FEV1) < 70% and presence of respiratory symptoms 
measured with the mMRC dyspnoea scale (mMRC > 2). Treatment effect, expressed 
as change FEV1 from baseline, was estimated from a 24 week-head-to-head phase 
III clinical trial comparing UMEC/VI with TIO and was assumed to last 52 weeks 
following treatment initiation (maximum duration of UMEC/VI clinical trials). 
Spanish utility values were derived from a published local observational study. 
Unitary healthcare costs (€ 2015) were obtained from local sources. A 3-year time 
horizon was selected and 3% discount was applied to effects and costs. Results were 
expressed as cost/quality adjusted life years (QALY). Univariate and probabilistic 
sensitivity analysis (PSA) were performed. Results: UMEC/VI produced additional 
0.03 QALY and 590€ versus TIO, leading to an ICER of 21,475€ /QALY. According to PSA, 
the probability of UMEC/VI being cost-effective was 80.3% at a willingness-to-pay 
of 30,000€ /QALY. ConClusions: UMEC/VI could be considered as a cost-effective 
treatment alternative compared with TIO in symptomatic COPD patients from the 
Spanish NHS perspective.
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objeCtives: Tiotropium (TIO), Spiriva Handihaler, is a well-established broncho-
dilator, LAMA (long-acting anticholinergic), for the treatment of moderate to very 
severe COPD. Clinical evidence from the SPARK trial suggests that TIO is superior to 
glycopyrronium (GLY), Seebri Breezhaler, in preventing severe exacerbations. This 
study assessed the cost-effectiveness of TIO versus GLY for Spain making use of 
this new clinical evidence. Methods: A Markov cohort model, with GOLD II – IV 
patients, was populated with efficacy data from the UPLIFT and SPARK trials as 
well as Spanish costs, utilities and epidemiological data. Treatment efficacy was 
modelled as improvements in lung function, quality-adjusted life years and as a 
lowering of the risk of exacerbations (rate of exacerbations). Relative efficacy of 
preventing exacerbations differed between treatment cohorts based on data from 
SPARK. Health and cost outcomes were simulated over an approximate life time 
horizon, starting from an age of 65 years. Robustness of results was validated in 
deterministic and probabilistic sensitivity analyses. Results: Over the life-time 
horizon, patients treated with TIO and GLY accumulated € 41,129 and € 40,063 respec-
tively in direct costs (€ 2014). TIO generated more QALYs (7.77) compared to GLY 
(7.52). In incremental terms TIO gained 0.25 QALYs compared to GLY at an incre-
mental cost of € 1,066, resulting in a cost per QALY gained of € 4,281 (cost and health 
outcomes discounted at 3% per annum). The results were mainly driven by the 
relative risk of severe exacerbations found in SPARK (RR GLY/TIO: 1.43 CI 1.05-1.97, 
P 0.025). ConClusions: The results from this study show that TIO is a highly cost-
effective treatment compared to GLY in moderate to very severe COPD. The cost per 
QALY is well-below the willingness-to-pay threshold for Spain (€ 30,000).
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objeCtives: To estimate the Cost-Effectiveness of Fluticasone propionate/
Formoterol fumarate (FPF) versus Fluticasone/Salmeterol (FS) and Budesonide/
Formoterol (BF) in the treatment of adult patients with moderate to severe asthma 
from the perspective of the Society in Spain. Methods: A Markov model was 
developed with five asthma health states: successful control, sub-optimal control, 
outpatient-managed exacerbation, inpatient-managed exacerbation, and death. 
Time horizon was set at 12 months. Weekly transition probabilities were derived 
from previous international and Spanish publications. Indirect resources utilization 
were obtained from a published Spanish study to ascertain healthcare resources 
utilization, identified as lost-workday-equivalents, and corresponding costs related 
with treatment of asthma in the year 2014. Effectiveness was expressed as qual-
ity-adjusted life years (QALY) gained. The cost-effectiveness was expressed as an 
incremental cost effectiveness ratio (ICER). Univariate and probabilistic sensitivity 
analysis (SA) were also applied. Results: FPF drug acquisition cost was lower (20% 
compared to FS and 30% compared to BF), whilst QALY of the three alternatives 
compared were very similar. Cost per patient on the FPF cohort yielded € 9,326/year, 
being the lowest price alternative: -1.5% compared to FS and -2.6% compared to BF. 
The sub-optimal control health state was the mainstay of costs (80% of total costs) 
in any of the analyzed alternatives and the scenarios. SA results confirmed the data 
from the base case scenario. ConClusions: From the Spanish societal perspective 
in year 2014, FPF produced similar QALY gain at a lower cost when compared with 
FS and BF in a highly meaningful number of replications and scenarios. FPF may 
be considered a cost-effective alternative in the treatment of moderate to severe 
asthma in Spain. The cost savings were mainly due to significant FPF lower price 
acquisition costs compared to the other two alternatives.
